Table 1.
Characteristics and Endpoint definitions of included randomized trials
| Study | Year | Location | Number | Study design | Primary endpoint | Definition of TLF | Definition of ST | Follow up (months) | Lost to FU (%) |
|---|---|---|---|---|---|---|---|---|---|
| AIDA | 2017 | Multicenter | 1845 | RCT | TVF | Cardiac death, TVMI, ID-TLR |
ARC | 24 | 2.8 |
| ABSORB III | 2017 | Multicenter | 2008 | RCT | TLF | Cardiac death, TVMI, ID-TLR |
ARC | 24 | 2.1 |
| ABSORB China | 2016 | Multicenter | 480 | RCT | IS-LL | Cardiac death, TVMI, ID-TLR |
ARC | 24 | 3.7 |
| ABSORB II | 2016 | Multicenter | 501 | RCT | Vasomotion, MLD | Cardiac death, TVMI, ID-TLR |
ARC | 24 | 4.2 |
| ABSORB Japan | 2016 | Multicenter | 400 | RCT | TLF | Cardiac death, TVMI, ID-TLR |
ARC | 24 | 3 |
Abbreviations: TLF target lesion failure, TVF target vessel failure, IS-LL in-segment late loss, MLD minimal lumen diameter, TVMI target vessel myocardial infarction, ID-TLR ischemia driven target lesion revascularization, RCT randomized clinical trials